Loading
Gastric fundal mucosal ablation (GFMA), Bariatric endoscopic antral myotomy (BEA / Bariatric Endoscopy / Obesity & Overweight · Phase 2 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registry record for a combined endoscopic bariatric procedure (gastric fundal mucosal ablation plus antral myotomy) in obesity. No results have been posted; the trial is currently recruiting. The study aims to measure weight loss and BMI change at 6 months as primary endpoints.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Obesity & Overweight, Bariatric Endoscopy; age from 18 Years. Intervention: Intervention arm. n = 10. 1 site: Egypt.
This is a Phase 2 registry record for a combined endoscopic bariatric procedure (gastric fundal mucosal ablation plus antral myotomy) in obesity. No results have been posted; the trial is currently recruiting. The study aims to measure weight loss and BMI change at 6 months as primary endpoints.
No safety, tolerability, or durability data provided.
Clinicians should not base practice decisions on this registry record. Once results are posted, they may inform the role of combined endoscopic fundal ablation and antral myotomy in bariatric treatment; however, the small Phase 2 sample will require larger confirmatory trials before adoption.
This is a Phase 2 trial registration with no posted results; the study is actively recruiting and has not yet reported efficacy or safety outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should not base practice decisions on this registry record. Once results are posted, they may inform the role of combined endoscopic fundal ablation and antral myotomy in bariatric treatment; however, the small Phase 2 sample will require larger confirmatory trials before adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07612527). This is a study registration, not published results. Lead sponsor: Cairo University. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 10 participants (ESTIMATED). Conditions: Obesity & Overweight, Bariatric Endoscopy. Interventions: PROCEDURE: Gastric fundal mucosal ablation (GFMA), Bariatric endoscopic antral myotomy (BEAM). Primary outcome measures: Total body weight loss , 6 months; BMI change from baseline , 6 months. Brief summary: The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways. Accordingly, endoscopic gastric fundal mucosal ablation (GFMA) may benefit patients with obesity. Ablation not only affects these mechanisms, but similar to what happens after mucosal ablation for other indications (e.g. ESD for tumor removal), it is expected to cause shrinking of the fundus and reduce gastric volume. Another potential target to achieve weight loss is gastric emptying. This is a critical step in digestion that has been found to be more rapid after prolonged exposure to a high-fat diet in both animal and human studies, with rapid emptying also being more common in young people with obesity in some studies. The bariatric endoscopic antral myotomy (BEAM) procedure has been shown to consistently delay gastric emptying without triggering symptoms of gastroparesis and to produce substantial weight loss. Both GFMA and BEAM procedures have the advantages of being minimally invasive, performed completely endoscopic and less costly than surgical alternatives or other known endoscopic techniques like intragastric balloon or endoscopic sleeve gastroplasty.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.